Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.6800
-0.08-10.53%
At close: -
$0.7900
0.1116.18%
After Hours: 9:13 AM EDT
Comments
Loading...
Connect Biopharma Hldgs Analyst Ratings and Price Targets | NASDAQ:CNTB | Benzinga
Connect Biopharma Holdings Ltd has a consensus price target of $5.38 based on the ratings of 4 analysts. The high is $8 issued by HC Wainwright & Co. on September 6, 2024. The low is $1.5 issued by Piper Sandler on May 5, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on September 6, 2024, June 13, 2024, and April 17, 2024, respectively. With an average price target of $8 between HC Wainwright & Co., there's an implied 912.66% upside for Connect Biopharma Holdings Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
SVB Leerink
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Connect Biopharma Hldgs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 09/06/2024 | Buy Now | 912.66% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2024 | Buy Now | 912.66% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 912.66% | HC Wainwright & Co. | Emily Bodnar39% | $7 → $8 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 786.08% | HC Wainwright & Co. | Emily Bodnar39% | → $7 | Initiates | → Buy | Get Alert |
| 09/13/2023 | Buy Now | 532.91% | Cantor Fitzgerald | Louise Chen56% | → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 02/08/2023 | Buy Now | 786.08% | SVB Leerink | Thomas Smith33% | $9 → $7 | Maintains | Outperform | Get Alert |
| 06/02/2022 | Buy Now | 532.91% | Cantor Fitzgerald | Louise Chen56% | → $5 | Initiates | → Overweight | Get Alert |
| 05/05/2022 | Buy Now | 89.87% | Piper Sandler | Joseph Catanzaro41% | $25 → $1.5 | Downgrade | Overweight → Neutral | Get Alert |
| 05/04/2022 | Buy Now | 1039.24% | SVB Leerink | Thomas Smith33% | $22 → $9 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Connect Biopharma Hldgs (CNTB) stock?
The latest price target for Connect Biopharma Hldgs (NASDAQ:CNTB) was reported by HC Wainwright & Co. on September 6, 2024. The analyst firm set a price target for $8.00 expecting CNTB to rise to within 12 months (a possible 912.66% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Connect Biopharma Hldgs (CNTB)?
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ:CNTB) was provided by HC Wainwright & Co., and Connect Biopharma Hldgs reiterated their buy rating.
When was the last upgrade for Connect Biopharma Hldgs (CNTB)?
There is no last upgrade for Connect Biopharma Hldgs
When was the last downgrade for Connect Biopharma Hldgs (CNTB)?
The last downgrade for Connect Biopharma Holdings Ltd happened on May 5, 2022 when Piper Sandler changed their price target from $25 to $1.5 for Connect Biopharma Holdings Ltd.
When is the next analyst rating going to be posted or updated for Connect Biopharma Hldgs (CNTB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.
Is the Analyst Rating Connect Biopharma Hldgs (CNTB) correct?
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a reiterated with a price target of $8.00 to $8.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $0.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.